QPPV.COM KNOWLEDGE ASSESSMENT

Eptinezumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Eptinezumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which combination of information would most appropriately support assessment of a suspected serious neurological or vascular event after eptinezumab?

Blood pressure, neurological examination, relevant imaging or cardiac assessment, vascular history, concomitant medicines and outcome Only the patient's statement that the event felt similar to a migraine Only the infusion batch number Only the time between two preventive doses

Question 2 of 10 During inspection, which evidence would best demonstrate that a pharmacovigilance system is functioning effectively for eptinezumab?

A written procedure exists, regardless of case completeness Cases show reliable reconstruction from source information through medical assessment, follow-up, aggregate review and regulatory decision Every report is assigned a definitive causal classification All follow-up requests are counted, even when no useful information is obtained

Question 3 of 10 Why is route of administration a meaningful pharmacovigilance classification axis for eptinezumab?

Intravenous administration creates a defined exposure chronology and opportunities to assess administration reactions, observation and batch traceability Route determines that every event after dosing is immune-mediated Route removes the need to document formulation and presentation Intravenous administration means preventive treatment should be assessed as acute analgesia

Question 4 of 10 Which approach is most appropriate for signal detection involving eptinezumab?

Use preferred-term counts alone to determine causality Stratify by relevant indication, disease severity, treatment line, regimen, duration, age, prior treatment and product presentation Pool all reports regardless of indication or treatment phase to maximize sample size Exclude concomitant medicines because they complicate interpretation

Question 5 of 10 Which statement best captures the relationship between a plausible mechanism and causality assessment?

A plausible pathway proves that the product caused the event A plausible pathway strengthens a hypothesis, but phenotype, timing, objective evidence, dechallenge and competing causes remain necessary Mechanism is irrelevant if the event is serious Mechanism can replace documentation of exposure dates and outcome

Question 6 of 10 A patient reports a headache two days after an eptinezumab infusion. Which initial pharmacovigilance approach is most appropriate?

Automatically classify it as an infusion reaction because it followed administration Classify it as treatment failure without reviewing baseline migraine activity Phenotype the headache and assess migraine fluctuation, acute medicines, medication overuse and alternative diagnoses Exclude a drug relationship because headaches are part of the underlying disease

Question 7 of 10 Which finding would most weaken an initial hypothesis that worsening headaches are caused by eptinezumab?

The headaches began after exposure The patient had a documented increase in headaches before treatment and substantial medication overuse The patient received the product intravenously The product is a monoclonal antibody

Question 8 of 10 Which is the most defensible professional conclusion when a case has plausible timing but incomplete objective findings and a strong competing diagnosis?

The event is definitively caused by eptinezumab The relationship should be described with calibrated uncertainty and may be more consistent with the competing diagnosis The case must be rejected because causality cannot be proven The event should be labelled immune-mediated because the product is biological

Question 9 of 10 A periodic safety review identifies more reports after eptinezumab use expanded to new treatment settings. What is the most appropriate interpretation?

The increase automatically proves a new product risk The review should distinguish original development evidence from post-authorisation evidence and examine changing exposure denominators and clinical contexts All later reports should be excluded because they were not from clinical trials The number of reports alone is sufficient without considering exposure

Question 10 of 10 What is the most appropriate mechanism-led description of eptinezumab's intended pharmacological action?

It binds circulating CGRP and reduces CGRP-mediated trigeminovascular signalling It directly dissolves cerebral thrombi during an acute migraine attack It suppresses all immune-cell activity throughout the body It increases CGRP release to restore normal vascular tone

QPPV.com

Eptinezumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings